AGM
ATOS icon

Alpine Global Management’s Atossa Therapeutics ATOS Stock Holding History

Alpine Global Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,090
Closed -$13.6K – 247
2025
Q2 		$13.6K Buy
+1,090
New +$13K ﹤0.01% 150
2024
Q3 		– Sell
-811
Closed -$14.5K – 179
2024
Q2 		$14.5K Buy
+811
New +$17.9K ﹤0.01% 453
2022
Q3 		– Sell
-2,473
Closed -$40K – 474
2022
Q2 		$40K Buy
+2,473
New +$39K 0.01% 172

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Alpine Global Management's ATOS Position: Q3 2025 in Review

Alpine Global Management sold out of Atossa Therapeutics (ATOS) in Q3 2025, closing a stake of 1,090 shares — an estimated $13.6K sold.

Alpine Global Management first reported a position in ATOS in Q2 2022 and held it in 3 quarters. The position peaked at $40K in Q2 2022. 66 funds tracked by Wall St. Rank hold ATOS as of Q3 2025.

  • Alpine Global Management reported no remaining Atossa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Alpine Global Management sold 1,090 Atossa Therapeutics shares in Q3 2025, an estimated $13.6K.
  • Alpine Global Management first reported a position in Atossa Therapeutics in Q2 2022 and held it in 3 quarters.
  • Alpine Global Management's Atossa Therapeutics position peaked at $40K in Q2 2022.
  • 66 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2025.

Based on Alpine Global Management's 13F filing for Q3 2025, filed 14 Nov 2025.